A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 01 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipatasertib (Primary) ; Rucaparib (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Roche

20 Jun 2023 Results assessing safety and efficacy of ipatasertib in patients with metastatic castration-resistant prostate cancer, published in the Clinical Cancer Research.
19 Feb 2022 Results of an analysis assessing the the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer presented at the 2022 Genitourinary Cancers Symposium
20 Jan 2022 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com